Dr. Kazai Anita

A fenntartó azathioprin-terápiában részesülő anyák és csecsemőik egészsége szempontjából is hasznos a szoptatás, nem nő a fertőzéses és tumoros megbetegedések kockázata a gyermekek között.

A gyulladásos bélbetegség (IBD) gyakran manifesztálódik fogamzó korú nőkben. A fogamzás vagy a terhesség alatti aktív betegség növeli a spontán abortusz, a halvaszületés, a koraszülés, az alacsony születési súly és a fejlődési rendellenességek kockázatát. Mindez azt igazolja, hogy nagyon fontos a klinikai remisszió elérése a fogamzás előtti időszakban és hatékony fenntartó kezelés alkalmazása a terhesség során. Az azathioprint (AZA) és metabolitját, a 6-merkaptopurint (6-MP) az IBD-betegek széles körében alkalmazzák fenntartó terápiaként, és napjainkban már a terhesség során is ajánlják folyamatos használatukat.
-> Olvasd el a teljes cikket. <-

ACR Manual on Contrast Media, Version 10.2 (2016)
American College of Radiology Committee on Drugs and Contrast Media

Imaging studies requiring either iodinated or gadolinium-based contrast media are occasionally required in patients who are breast feeding. Both the patient and the patient’s physician may have concerns regarding potential toxicity to the infant from contrast media that is excreted into the breast milk.

The literature on the excretion into breast milk of iodinated and gadolinium-based contrast media and the gastrointestinal absorption of these agents from breast milk is very limited; however, several studies have shown that the expected dose of contrast medium absorbed by an infant from ingested breast milk is extremely low

Az útmutató teljes szövege letölthető innen.
-> Olvasd el a teljes cikket. <-

Henderson E, Mackillop L.
Postgrad Med J. 2011 May;87(1027):349-54.

Abstract

Prescribing in pregnancy often causes uncertainty and anxiety for the clinician and may lead to the omission of necessary treatment. Many drugs have inadequate data to assure safety, and therefore the clinician is left with a dilemma as to where the balance of risks and benefits lie with respect to the mother and her fetus. Understanding under what circumstances women can be prescribed medication and using principles of prescribing in pregnancy to further clarify the potential risks will aid good clinical decision-making. An appreciation of the available resources and the conviction to find the best available evidence will best serve the patient and her fetus.
-> Olvasd el a teljes cikket. <-

Hale TW, Kendall-Tackett K, Cong Z, Votta R, McCurdy F.
Breastfeed Med. 2010 Dec;5(6):283-8.

Abstract

OBJECTIVEThis study compared mothers’ report of symptoms of discontinuation syndrome in infants exposed to antidepressants both in utero and during lactation to infants who were exposed only during lactation.

STUDY DESIGN: This is a convenience sample of 930 women breastfeeding women who answered an online questionnaire about antidepressant use while pregnant and breastfeeding. All 930 women had taken antidepressants while breastfeeding, and 527 had also taken antidepressants during pregnancy. There were no participants in the present study who had taken antidepressants only during pregnancy. The questionnaire was posted on the first author’s Medications and Breastfeeding Forum.
-> Olvasd el a teljes cikket. <-

Miranda So, Pina Bozzo, Miho Inoue and Adrienne Einarson
Can Fam Physician Vol. 56, No. 5, May 2010, pp.427 – 429

QUESTION Many of my pregnant and breastfeeding patients suffer from allergies and frequently ask me about the safety of antihistamines during pregnancy and breastfeeding. Should I advise them to use the older sedating medications? I have heard that they might be safer than the newer nonsedating class of drugs. Or have the newer ones been studied as well?

ANSWER First-generation antihistamines are considered safe to use during pregnancy. There are relatively fewer data on the nonsedating second-generation antihistamines; however, published studies are reassuring.
-> Olvasd el a teljes cikket. <-